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INTRODUCTION: Diabetes Mellitus is one of the major
chronic diseases in Western societies, causing considerable
comorbidity of cardiovascular diseases and premature death.
Because of the variety of risk factors for diabetes mellitus and
different macrovascular complications, the set of potentially
interesting interventions is quite large. For policy makers with
limited budgets, the question thus arises in what area of diabetes
prevention, health care money is spent most effectively. OBJEC-
TIVE: The aim of the present study was to review the literature
on economic evaluation of interventions for prevention of dia-
betes Type-2 or its macrovascular complications, to describe
their results and to identify the interventions that require addi-
tional research. METHODS: A systematic review of the litera-
ture was conducted. The interventions were classiﬁed by type of
prevention. The characteristics of the selected studies (with life
years gained or quality adjusted life years as an outcome
measure) were described in a database, to generate summary
tables. To be included, studies had to give a full economic eval-
uation of effects of the intervention. All studies were scored for
quality using the BMJ checklist. RESULTS: In total 23 studies
with life years gained or quality adjusted life years as an outcome
measure were selected. Two studies focused on primary preven-
tion, one on screening, and 20 studies evaluated interventions
for the prevention of macrovascular complications. CONCLU-
SIONS: Tight blood pressure control is a cost effective interven-
tion compared to less tight control. Medication to reduce both
overweight and hyperglycemia was found to be cost saving to
moderately cost-effective. Primary prevention of Type-2 diabetes
also appeared to be cost-effective and cost saving, but further
research is needed because only two studies were available. The
results of medication interventions to reduce overweight, to
reduce hyperglycemia, and to reduce dyslipidemia vary consid-
erably, warranting further economic analysis to identify cost-
effective strategies.
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OBJECTIVES: Our objective was to develop a lifetime model of
Type-2 diabetes mellitus and its sequelae in order to compare the
costs and beneﬁts of pioglitazone versus rosiglitazone oral treat-
ment. METHODS: A decision-analytic model employing a
Monte Carlo simulation of a Markov process was constructed.
The model incorporated efﬁcacy data from a large (n = 802) key
clinical trial comparing the glycaemic and lipid control of piogli-
tazone and rosiglitazone (Study H6E-US-GLAI). These efﬁcacy
data were used with a recently published UKPDS algorithm to
calculate the risk of diabetic complications, including mortality,
as patients progressed through each treatment arm in the model.
The model was calculated from the perspective of the National
Health Service in the UK and included direct health care costs
only. Patient outcomes measured in the model included life-
expectancy and quality-adjusted life-expectancy. RESULTS:
Patients treated with pioglitazone achieved a reduction in their
total cholesterol to high-density lipoprotein ratio (TC:HDL) of
0.34 whereas the TC:HDL increased by 0.65 in those receiving
rosiglitazone (p < 0.001). The HbA1c proﬁle was similar
between the treatment groups (p = 0.13). Other known risk
factors for diabetes complications were also found to be similar.
The lifetime health care costs per-patient estimated by the model
were £9585 for pioglitazone and £10,299 for rosiglitazone.
Patients treated with pioglitazone had a discounted life-
expectancy of 8.83 years versus 8.79 years for rosiglitazone
patients. Pioglitazone patients also experienced additional
quality-adjusted life-years (6.8070 vs. 6.7686). With improved
health outcomes and lower costs, treatment with pioglitazone
dominated rosiglitazone treatment. CONCLUSIONS: High
quality evidence from a large head-to-head trial indicates supe-
rior serum lipid proﬁles and similar HbA1c proﬁle in patients
treated with pioglitazone. In addition, treatment with pioglita-
zone is associated with lower costs than rosiglitazone. It follows
that pioglitazone is the cost-effective treatment choice for this
patient population.
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OBJECTIVES: To perform an economic evaluation of once-daily
insulin glargine plus oral antidiabetic therapy (BOT) versus
twice-daily administration of pre-mixed insulin (30/70) based on
the LAPTOP-Study results from the German health insurance’s
(GKV) perspective. METHODS: A cost-minimization analysis
was performed from the GKV viewpoint taking into account
insulin-naïve type-2 diabetes mellitus patients poorly controlled
with oral antidiabetic drugs (OAD). First year of insulin treat-
ment was analyzed. Costs included medication, application
devices and blood sugar control. Other costs were either the
same in both groups or not relevant for the GKV perspective.
Underlying prices were retail prices. Insulin use for the ﬁrst 24
weeks and OAD use were taken from the study results, blood
sugar control followed the study’s recommendations. Insulin use
for weeks 25 to 52 was extrapolated. Although the study results
showed a slight improvement in the BOT arm we assumed equal-
ity. Univariate sensitivity analyses were performed to account for
uncertainties. RESULTS: Annual insulin use was 10,500I.U. and
23,900I.U. in the BOT and pre-mixed insulin group, respec-
tively. Assuming base-case conditions overall annual costs were
€236 lower for the BOT regimen. Parameter variation of +/-20%
still kept the difference between the regimens negative, i.e.,
favourable for BOT. Also some variations reﬂecting potential dif-
ferences between the study results and German treatment reality
were all favourable for BOT. If varied individually, insulin prices
and insulin use had the highest impact, but if insulin use and
prices were varied in both groups simultaneously, the number of
blood sugar controls per day had the highest impact. CON-
CLUSIONS: In Germany, BOT with insulin glargine is a cost-
saving form of therapy compared to twice-daily pre-mixed
insulin during the ﬁrst year of treatment in type-2 diabetes
patients poorly controlled with OAD drug treatment.
